{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=DEXAMETHASONE&page=10", "query": { "intervention": "DEXAMETHASONE", "page": 10 }, "page_size": 10 }, "pagination": { "page": 10, "page_size": 10, "total_count": 1868, "total_pages": 187, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=DEXAMETHASONE&page=11&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=DEXAMETHASONE&page=9&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-23T14:24:13.091Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04860518", "title": "Human Intravenous Interferon Beta-Ia Safety and Preliminary Efficacy in Hospitalized Subjects With COVID-19", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Covid19" ], "interventions": [ { "name": "IFN beta-1a", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Faron Pharmaceuticals Ltd", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2021-08-23", "completion_date": "2022-04-04", "has_results": true, "last_update_posted_date": "2023-07-21", "last_synced_at": "2026-10-23T14:24:13.091Z", "location_count": 4, "location_summary": "Aurora, Colorado • Boston, Massachusetts • Newton, Massachusetts + 1 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Newton", "state": "Massachusetts" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT04860518" }, { "nct_id": "NCT03012880", "title": "Ixazomib Citrate, Lenalidomide, Dexamethasone, and Daratumumab in Treating Patients With Newly Diagnosed Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Plasma Cell Myeloma" ], "interventions": [ { "name": "Daratumumab", "type": "BIOLOGICAL" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Ixazomib Citrate", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2017-04-20", "completion_date": "2022-12-15", "has_results": true, "last_update_posted_date": "2025-06-04", "last_synced_at": "2026-10-23T14:24:13.091Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT03012880" }, { "nct_id": "NCT00906503", "title": "Fludeoxyglucose F 18-PET/CT Scans in Patients Receiving Ultra Short-Term Dexamethasone For Lung Nodules", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pulmonary Nodule" ], "interventions": [ { "name": "dexamethasone", "type": "DRUG" }, { "name": "PET/Computed Tomography (CT)", "type": "PROCEDURE" }, { "name": "fludeoxyglucose (18F)", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Barbara Ann Karmanos Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2009-04", "completion_date": "2012-04", "has_results": true, "last_update_posted_date": "2015-04-07", "last_synced_at": "2026-10-23T14:24:13.091Z", "location_count": 2, "location_summary": "Detroit, Michigan", "locations": [ { "city": "Detroit", "state": "Michigan" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00906503" }, { "nct_id": "NCT02188173", "title": "An Observational Study of OZURDEX® in Diabetic Macular Edema (DME)", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Macular Edema" ], "interventions": [ { "name": "dexamethasone 700 ㎍ intravitreal implant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Allergan", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 200, "start_date": "2014-07", "completion_date": "2016-05", "has_results": false, "last_update_posted_date": "2016-06-01", "last_synced_at": "2026-10-23T14:24:13.091Z", "location_count": 18, "location_summary": "Phoenix, Arizona • San Francisco, California • Santa Ana, California + 15 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "San Francisco", "state": "California" }, { "city": "Santa Ana", "state": "California" }, { "city": "Walnut Creek", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT02188173" }, { "nct_id": "NCT07084441", "title": "Comparison of Outcomes of Management of Bowel Obstruction", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Adhesive Small Bowel Obstruction" ], "interventions": [ { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Supportive Care", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 550, "start_date": "2026-02-03", "completion_date": "2030-12", "has_results": false, "last_update_posted_date": "2026-05-07", "last_synced_at": "2026-10-23T14:24:13.091Z", "location_count": 4, "location_summary": "New York, New York • Seattle, Washington", "locations": [ { "city": "New York", "state": "New York" }, { "city": "Seattle", "state": "Washington" }, { "city": "Seattle", "state": "Washington" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT07084441" }, { "nct_id": "NCT05032183", "title": "Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Recurrent Adult Lymphoblastic Lymphoma", "Recurrent B Acute Lymphoblastic Leukemia", "Recurrent T Acute Lymphoblastic Leukemia", "Refractory B Acute Lymphoblastic Leukemia", "Refractory Lymphoblastic Lymphoma", "Refractory T Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Filgrastim-sndz", "type": "BIOLOGICAL" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Mercaptopurine", "type": "DRUG" }, { "name": "Mesna", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Pegfilgrastim", "type": "BIOLOGICAL" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Tagraxofusp-erzs", "type": "BIOLOGICAL" }, { "name": "Vincristine", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 4, "start_date": "2022-02-17", "completion_date": "2024-07-31", "has_results": true, "last_update_posted_date": "2025-08-11", "last_synced_at": "2026-10-23T14:24:13.091Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05032183" }, { "nct_id": "NCT06128369", "title": "A Phase 3 Study Evaluating the Efficacy and Safety of OCS-01 Opthalmic Suspension Compared to Vehicle for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Inflammation Eye Pain", "Postoperative Cataract" ], "interventions": [ { "name": "OCS-01", "type": "DRUG" }, { "name": "Vehicle", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Oculis", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 117, "start_date": "2023-12-18", "completion_date": "2024-05-09", "has_results": true, "last_update_posted_date": "2026-07-30", "last_synced_at": "2026-10-23T14:24:13.091Z", "location_count": 24, "location_summary": "Glendale, California • Inglewood, California • Newport Beach, California + 21 more", "locations": [ { "city": "Glendale", "state": "California" }, { "city": "Inglewood", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Torrance", "state": "California" }, { "city": "Tamarac", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06128369" }, { "nct_id": "NCT00600353", "title": "Multi-day Doses in Prevention of Nausea and Emesis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myeloma, Plasma-Cell", "Lymphoma, Malignant" ], "interventions": [ { "name": "Palonosetron", "type": "DRUG" }, { "name": "Aprepitant", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Kansas Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2007-10", "completion_date": "2010-01", "has_results": true, "last_update_posted_date": "2017-03-09", "last_synced_at": "2026-10-23T14:24:13.091Z", "location_count": 1, "location_summary": "Kansas City, Kansas", "locations": [ { "city": "Kansas City", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00600353" }, { "nct_id": "NCT04413253", "title": "Xiidra vs. Xiidra + Dextenza Treatment for Dry Eye Disease", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Dry Eye Syndromes" ], "interventions": [ { "name": "Lifitegrast 5% Ophthalmic Solution", "type": "DRUG" }, { "name": "Dexamethasone Intracanalicular Insert, 0.4mg with Lifitegrast 5% Ophthalmic Solution", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eye Surgeons of Indiana", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 5, "start_date": "2020-08-01", "completion_date": "2022-04-11", "has_results": false, "last_update_posted_date": "2022-04-18", "last_synced_at": "2026-10-23T14:24:13.091Z", "location_count": 1, "location_summary": "Indianapolis, Indiana", "locations": [ { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT04413253" }, { "nct_id": "NCT04181827", "title": "A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Cilta-cel", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 419, "start_date": "2020-06-12", "completion_date": "2027-03-31", "has_results": true, "last_update_posted_date": "2026-09-28", "last_synced_at": "2026-10-23T14:24:13.091Z", "location_count": 19, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Stanford, California + 16 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Stanford", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT04181827" } ] }